Pelter Michele M, Kozik Teri M, Loranger Denise L, Carey Mary G
Orvis School of Nursing, University of Nevada, Reno, Nevada, USA.
J Vis Exp. 2012 Dec 28(70):50124. doi: 10.3791/50124.
Each year, an estimated 785,000 Americans will have a new coronary attack, or acute coronary syndrome (ACS). The pathophysiology of ACS involves rupture of an atherosclerotic plaque; hence, treatment is aimed at plaque stabilization in order to prevent cellular death. However, there is considerable debate among clinicians, about which treatment pathway is best: early invasive using percutaneous coronary intervention (PCI/stent) when indicated or a conservative approach (i.e., medication only with PCI/stent if recurrent symptoms occur). There are three types of ACS: ST elevation myocardial infarction (STEMI), non-ST elevation MI (NSTEMI), and unstable angina (UA). Among the three types, NSTEMI/UA is nearly four times as common as STEMI. Treatment decisions for NSTEMI/UA are based largely on symptoms and resting or exercise electrocardiograms (ECG). However, because of the dynamic and unpredictable nature of the atherosclerotic plaque, these methods often under detect myocardial ischemia because symptoms are unreliable, and/or continuous ECG monitoring was not utilized. Continuous 12-lead ECG monitoring, which is both inexpensive and non-invasive, can identify transient episodes of myocardial ischemia, a precursor to MI, even when asymptomatic. However, continuous 12-lead ECG monitoring is not usual hospital practice; rather, only two leads are typically monitored. Information obtained with 12-lead ECG monitoring might provide useful information for deciding the best ACS treatment. Purpose. Therefore, using 12-lead ECG monitoring, the COMPARE Study (electroCardiographic evaluatiOn of ischeMia comParing invAsive to phaRmacological trEatment) was designed to assess the frequency and clinical consequences of transient myocardial ischemia, in patients with NSTEMI/UA treated with either early invasive PCI/stent or those managed conservatively (medications or PCI/stent following recurrent symptoms). The purpose of this manuscript is to describe the methodology used in the COMPARE Study. Method. Permission to proceed with this study was obtained from the Institutional Review Board of the hospital and the university. Research nurses identify hospitalized patients from the emergency department and telemetry unit with suspected ACS. Once consented, a 12-lead ECG Holter monitor is applied, and remains in place during the patient's entire hospital stay. Patients are also maintained on the routine bedside ECG monitoring system per hospital protocol. Off-line ECG analysis is done using sophisticated software and careful human oversight.
每年,估计有78.5万美国人会发生新的冠状动脉发作,即急性冠状动脉综合征(ACS)。ACS的病理生理学涉及动脉粥样硬化斑块破裂;因此,治疗旨在稳定斑块以防止细胞死亡。然而,临床医生对于哪种治疗途径最佳存在相当大的争议:在有指征时采用经皮冠状动脉介入治疗(PCI/支架)的早期侵入性治疗,还是保守治疗方法(即仅在出现复发症状时使用药物并进行PCI/支架治疗)。ACS有三种类型:ST段抬高型心肌梗死(STEMI)、非ST段抬高型心肌梗死(NSTEMI)和不稳定型心绞痛(UA)。在这三种类型中,NSTEMI/UA的发生率几乎是STEMI的四倍。NSTEMI/UA的治疗决策很大程度上基于症状以及静息或运动心电图(ECG)。然而,由于动脉粥样硬化斑块具有动态性和不可预测性,这些方法常常无法充分检测到心肌缺血,因为症状不可靠,和/或未采用连续心电图监测。连续12导联心电图监测既便宜又无创,即使在无症状时也能识别心肌缺血的短暂发作,而心肌缺血是心肌梗死的先兆。然而,连续12导联心电图监测并非医院的常规做法;通常只监测两个导联。通过12导联心电图监测获得的信息可能为决定最佳的ACS治疗提供有用信息。目的。因此,COMPARE研究(比较侵入性与药物治疗的心肌缺血心电图评估)使用12导联心电图监测,旨在评估接受早期侵入性PCI/支架治疗或保守治疗(复发症状后使用药物或PCI/支架)的NSTEMI/UA患者短暂性心肌缺血的频率和临床后果。本手稿的目的是描述COMPARE研究中使用的方法。方法。该研究已获得医院和大学的机构审查委员会的批准。研究护士从急诊科和遥测病房中识别出疑似ACS的住院患者。一旦获得患者同意,就会应用12导联心电图动态监测仪,并在患者整个住院期间一直佩戴。根据医院规程,患者还会维持使用常规床边心电图监测系统。离线心电图分析使用复杂的软件并经过仔细的人工检查。